share_log

Merck & Co | 10-Q: Q3 2024 Earnings Report

Merck & Co | 10-Q: Q3 2024 Earnings Report

默沙东 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/07 05:08

Moomoo AI 已提取核心信息

Merck reported Q3 2024 revenue of $16.7 billion, up 4% year-over-year, driven by strong performance in oncology and cardiovascular franchises. Keytruda sales grew 17% to $7.4 billion, while newly launched Winrevair contributed $149 million. The company recorded charges of $2.2 billion related to acquisitions of EyeBio and MK-1045 from Curon.Operating performance was mixed as gross margin improved to 75.5% from 73.3%, while R&D expenses surged 77% to $5.9 billion due to acquisition-related charges. Net income declined to $3.2 billion from $4.7 billion in Q3 2023, with EPS of $1.24 versus $1.86 last year. The effective tax rate increased to 22.7% from 15.5%.Looking ahead, Merck faces headwinds from generic competition for Januvia/Janumet and lower Gardasil sales in China. The company maintained strong cash flow with $18 billion from operations year-to-date. The Board declared a quarterly dividend of $0.77 per share, while $817 million was spent on share repurchases in the first nine months.
Merck reported Q3 2024 revenue of $16.7 billion, up 4% year-over-year, driven by strong performance in oncology and cardiovascular franchises. Keytruda sales grew 17% to $7.4 billion, while newly launched Winrevair contributed $149 million. The company recorded charges of $2.2 billion related to acquisitions of EyeBio and MK-1045 from Curon.Operating performance was mixed as gross margin improved to 75.5% from 73.3%, while R&D expenses surged 77% to $5.9 billion due to acquisition-related charges. Net income declined to $3.2 billion from $4.7 billion in Q3 2023, with EPS of $1.24 versus $1.86 last year. The effective tax rate increased to 22.7% from 15.5%.Looking ahead, Merck faces headwinds from generic competition for Januvia/Janumet and lower Gardasil sales in China. The company maintained strong cash flow with $18 billion from operations year-to-date. The Board declared a quarterly dividend of $0.77 per share, while $817 million was spent on share repurchases in the first nine months.
默沙东报告了2024年第三季度营业收入为167亿，同比增长4%，主要受到肿瘤学和心血管领域强劲表现的推动。Keytruda的销售增长了17%，达到了74亿，而新推出的Winrevair贡献了14900万。公司记录了与从Curon收购EyeBio和Mk-1045相关的22亿费用。运营表现参差不齐，毛利率从73.3%提升至75.5%，而研发支出由于收购相关费用激增77%，达到了59亿。净利润从2023年第三季度的47亿下降至32亿，每股收益为1.24美元，去年为1.86美元。有效税率从15.5%上升至22.7%。展望未来，默沙东面临来自Januvia/Janumet的仿制药竞争和在中国的Gardasil销售下滑等挑战。公司保持了强劲的现金流，截至目前运营产生180亿现金。董事会宣布季度股息为每股0.77美元，同时在前九个月中花费了81700万用于股份回购。
默沙东报告了2024年第三季度营业收入为167亿，同比增长4%，主要受到肿瘤学和心血管领域强劲表现的推动。Keytruda的销售增长了17%，达到了74亿，而新推出的Winrevair贡献了14900万。公司记录了与从Curon收购EyeBio和Mk-1045相关的22亿费用。运营表现参差不齐，毛利率从73.3%提升至75.5%，而研发支出由于收购相关费用激增77%，达到了59亿。净利润从2023年第三季度的47亿下降至32亿，每股收益为1.24美元，去年为1.86美元。有效税率从15.5%上升至22.7%。展望未来，默沙东面临来自Januvia/Janumet的仿制药竞争和在中国的Gardasil销售下滑等挑战。公司保持了强劲的现金流，截至目前运营产生180亿现金。董事会宣布季度股息为每股0.77美元，同时在前九个月中花费了81700万用于股份回购。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    施贵宝
    BMY
    -- 60.020
    默沙东
    MRK
    -- 89.230
    赛诺菲安万特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯维公司
    ABBV
    -- 205.290
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日